Search

Your search keyword '"COKER, B"' showing total 110 results
Start Over Author "COKER, B"
110 results on '"COKER, B"'

1. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma

Author

Baker, A., Berry, L., Hatton, M., Henry, A., Lee, J., Patel, R., Powell, H., Sahdra, S., Slevin, N., Van As, N., Webster, G., Zou, L., Jin, H., Chalkidou, A., Hawkins, M., Summers, J., Eddy, S., Peacock, J.L., Coker, B., Kartha, M.R., Good, J., and Pennington, M.

Published
2021
Full Text
View/download PDF

3. Risk of severe COVID-19 associated with immune-modifying drugs: Data from PsoProtect and Global Rheumatology Alliance registries.

Author

Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, Smith CH., Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, and Smith CH.

Published
2022

5. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Author

Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Choon, S, Naldi, L, Lambert, J, Spuls, P, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Shah, A, Barea, A, Romero-Mate, A, Singapore, A, Paolino, A, Mwale, A, Morales Callaghan, A, Martinez, A, Decrescenzo, A, Pink, A, Jones, A, Sergeant, A, Essex, A, Bewley, A, Makrygeorgou, A, van Huizen, A, Perez-Suarez, B, Farida, B, Clareus, B, Prims, C, Davis, C, Quinlan, C, Maybury, C, Cesar, G, Barclay, C, Greco, C, Brassard, D, Cummings, D, Kolli, D, Descamps, V, Genao, D, Carras, E, Hawryluk, E, Martinez-Garcia, E, Klujszo, E, Dwyer, E, Toni, E, Sonkoly, E, Loayza, E, Dauden, E, Valenzuela, F, Popov, G, King, G, Celine, G, Aparicio, G, Johnston, G, Cardozo, G, Pearson, I, Yanguas, I, Weisman, J, Carolan, J, Hughes, J, Ortiz-Salvador, J, Carrascosa, J, Schwartz, J, Jackson, K, Kerisit, K, Wu, K, Asfour, L, de Graaf, L, Lesort, C, Meuleman, L, Eidsmo, L, Skov, L, Gribben, L, Rustin, M, Velasco, M, Panchal, M, Lakhan, M, Franco, M, Svensson, M, Vandaele, M, Marovt, M, Zargari, O, De Caso, P, Varela, P, Jenkin, P, Phan, C, Hampton, P, Goldsmith, P, Bak, R, Speeckaert, R, Romiti, R, Woolf, R, Mercado-Seda, R, Khatun, R, Ceovic, R, Taberner, R, Cohen, R, Stefanescu, S, Kirk, S, Reeken, S, Ayob, S, Perez-Barrio, S, Piaserico, S, Hoey, S, Torres, T, Talme, T, Desai, T, van Geest, A, King, V, Di Lernia, V, Koreja, Z, Hasab, V, Mahil S. K., Dand N., Mason K. J., Yiu Z. Z. N., Tsakok T., Meynell F., Coker B., McAteer H., Moorhead L., Mackenzie T., Rossi M. T., Rivera R., Mahe E., Carugno A., Magnano M., Rech G., Balogh E. A., Feldman S. R., De La Cruz C., Choon S. E., Naldi L., Lambert J., Spuls P., Jullien D., Bachelez H., McMahon D. E., Freeman E. E., Gisondi P., Puig L., Warren R. B., Di Meglio P., Langan S. M., Capon F., Griffiths C. E. M., Barker J. N., Smith C. H., Shah A., Barea A., Romero-Mate A., Singapore A., Paolino A., Mwale A., Morales Callaghan A. M., Martinez A., DeCrescenzo A., Pink A. E., Jones A., Sergeant A., Essex A., Bewley A., Makrygeorgou A., van Huizen A., Perez-Suarez B., Farida B., Clareus B. W., Prims C. T., Davis C., Quinlan C., Maybury C., Cesar G. A., Barclay C., Greco C., Brassard D., Cummings D., Kolli D., Descamps V., Genao D. R., Carras E., Hawryluk E., Martinez-Garcia E., Klujszo E., Dwyer E., Toni E., Sonkoly E., Loayza E., Dauden E., Valenzuela F., Popov G., King G., Celine G., Aparicio G., Johnston G. A., Cardozo G. A., Pearson I., Yanguas I., Weisman J., Carolan J. E., Hughes J., Ortiz-Salvador J. -M., Carrascosa J. -M., Schwartz J. J., Jackson K., Kerisit K. G., Wu K., Asfour L., de Graaf L., Lesort C., Meuleman L., Eidsmo L., Skov L., Gribben L., Rustin M., Velasco M., Panchal M., Lakhan M., Franco M. D., Svensson M. -L., Vandaele M., Marovt M., Zargari O., De Caso P., Varela P., Jenkin P., Phan C., Hampton P., Goldsmith P., Bak R., Speeckaert R., Romiti R., Woolf R., Mercado-Seda R., Khatun R., Ceovic R., Taberner R., Cohen R. W., Stefanescu S., Kirk S., Reeken S., Ayob S., Perez-Barrio S., Piaserico S., Hoey S., Torres T., Talme T., Desai T. V., van Geest A. J., King V., Di Lernia V., Koreja Z., Hasab V. Z., Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Choon, S, Naldi, L, Lambert, J, Spuls, P, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Shah, A, Barea, A, Romero-Mate, A, Singapore, A, Paolino, A, Mwale, A, Morales Callaghan, A, Martinez, A, Decrescenzo, A, Pink, A, Jones, A, Sergeant, A, Essex, A, Bewley, A, Makrygeorgou, A, van Huizen, A, Perez-Suarez, B, Farida, B, Clareus, B, Prims, C, Davis, C, Quinlan, C, Maybury, C, Cesar, G, Barclay, C, Greco, C, Brassard, D, Cummings, D, Kolli, D, Descamps, V, Genao, D, Carras, E, Hawryluk, E, Martinez-Garcia, E, Klujszo, E, Dwyer, E, Toni, E, Sonkoly, E, Loayza, E, Dauden, E, Valenzuela, F, Popov, G, King, G, Celine, G, Aparicio, G, Johnston, G, Cardozo, G, Pearson, I, Yanguas, I, Weisman, J, Carolan, J, Hughes, J, Ortiz-Salvador, J, Carrascosa, J, Schwartz, J, Jackson, K, Kerisit, K, Wu, K, Asfour, L, de Graaf, L, Lesort, C, Meuleman, L, Eidsmo, L, Skov, L, Gribben, L, Rustin, M, Velasco, M, Panchal, M, Lakhan, M, Franco, M, Svensson, M, Vandaele, M, Marovt, M, Zargari, O, De Caso, P, Varela, P, Jenkin, P, Phan, C, Hampton, P, Goldsmith, P, Bak, R, Speeckaert, R, Romiti, R, Woolf, R, Mercado-Seda, R, Khatun, R, Ceovic, R, Taberner, R, Cohen, R, Stefanescu, S, Kirk, S, Reeken, S, Ayob, S, Perez-Barrio, S, Piaserico, S, Hoey, S, Torres, T, Talme, T, Desai, T, van Geest, A, King, V, Di Lernia, V, Koreja, Z, Hasab, V, Mahil S. K., Dand N., Mason K. J., Yiu Z. Z. N., Tsakok T., Meynell F., Coker B., McAteer H., Moorhead L., Mackenzie T., Rossi M. T., Rivera R., Mahe E., Carugno A., Magnano M., Rech G., Balogh E. A., Feldman S. R., De La Cruz C., Choon S. E., Naldi L., Lambert J., Spuls P., Jullien D., Bachelez H., McMahon D. E., Freeman E. E., Gisondi P., Puig L., Warren R. B., Di Meglio P., Langan S. M., Capon F., Griffiths C. E. M., Barker J. N., Smith C. H., Shah A., Barea A., Romero-Mate A., Singapore A., Paolino A., Mwale A., Morales Callaghan A. M., Martinez A., DeCrescenzo A., Pink A. E., Jones A., Sergeant A., Essex A., Bewley A., Makrygeorgou A., van Huizen A., Perez-Suarez B., Farida B., Clareus B. W., Prims C. T., Davis C., Quinlan C., Maybury C., Cesar G. A., Barclay C., Greco C., Brassard D., Cummings D., Kolli D., Descamps V., Genao D. R., Carras E., Hawryluk E., Martinez-Garcia E., Klujszo E., Dwyer E., Toni E., Sonkoly E., Loayza E., Dauden E., Valenzuela F., Popov G., King G., Celine G., Aparicio G., Johnston G. A., Cardozo G. A., Pearson I., Yanguas I., Weisman J., Carolan J. E., Hughes J., Ortiz-Salvador J. -M., Carrascosa J. -M., Schwartz J. J., Jackson K., Kerisit K. G., Wu K., Asfour L., de Graaf L., Lesort C., Meuleman L., Eidsmo L., Skov L., Gribben L., Rustin M., Velasco M., Panchal M., Lakhan M., Franco M. D., Svensson M. -L., Vandaele M., Marovt M., Zargari O., De Caso P., Varela P., Jenkin P., Phan C., Hampton P., Goldsmith P., Bak R., Speeckaert R., Romiti R., Woolf R., Mercado-Seda R., Khatun R., Ceovic R., Taberner R., Cohen R. W., Stefanescu S., Kirk S., Reeken S., Ayob S., Perez-Barrio S., Piaserico S., Hoey S., Torres T., Talme T., Desai T. V., van Geest A. J., King V., Di Lernia V., Koreja Z., and Hasab V. Z.

Abstract

Background: The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited. Objective: Our aim was to characterize the course of COVID-19 in patients with psoriasis and identify factors associated with hospitalization. Methods: Clinicians reported patients with psoriasis with confirmed/suspected COVID-19 via an international registry, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection. Multiple logistic regression was used to assess the association between clinical and/or demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviors. Results: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% were receiving a nonbiologic, and 10% were not receiving any systemic treatment for psoriasis. In all, 348 patients (93%) were fully recovered from COVID-19, 77 (21%) were hospitalized, and 9 (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted odds ratio [OR] = 1.59 per 10 years; 95% CI = 1.19-2.13), male sex (OR = 2.51; 95% CI = 1.23-5.12), nonwhite ethnicity (OR = 3.15; 95% CI = 1.24-8.03), and comorbid chronic lung disease (OR = 3.87; 95% CI = 1.52-9.83). Hospitalization was more frequent in patients using nonbiologic systemic therapy than in those using biologics (OR = 2.84; 95% CI = 1.31-6.18). No significant differences were found between classes of biologics. Independent patient-reported data (n = 1626 across 48 countries) suggested lower levels of social isolation in individuals receiving nonbiologic systemic therapy than in those receiving biologics (OR = 0.68; 95% CI = 0.50-0.94). Conclusion: In this international case series of patients with moderate-to-severe psoriasis, biologic use was associated with lower risk of COVID-19–related hospitalization than with

Published
2021

6. Evaluation of the Growth Assessment Protocol (GAP) for antenatal detection of small for gestational age: The DESiGN cluster randomised trial.

Author

Vieira, MC, Relph, S, Muruet-Gutierrez, W, Elstad, M, Coker, B, Moitt, N, Delaney, L, Winsloe, C, Healey, A, Coxon, K, Alagna, A, Briley, A, Johnson, M, Page, LM, Peebles, D, Shennan, A, Thilaganathan, B, Marlow, N, McCowan, L, Lees, C, Lawlor, DA, Khalil, A, Sandall, J, Copas, A, Pasupathy, D, DESiGN Collaborative Group, Vieira, MC, Relph, S, Muruet-Gutierrez, W, Elstad, M, Coker, B, Moitt, N, Delaney, L, Winsloe, C, Healey, A, Coxon, K, Alagna, A, Briley, A, Johnson, M, Page, LM, Peebles, D, Shennan, A, Thilaganathan, B, Marlow, N, McCowan, L, Lees, C, Lawlor, DA, Khalil, A, Sandall, J, Copas, A, Pasupathy, D, and DESiGN Collaborative Group

Abstract

BACKGROUND: Antenatal detection and management of small for gestational age (SGA) is a strategy to reduce stillbirth. Large observational studies provide conflicting results on the effect of the Growth Assessment Protocol (GAP) in relation to detection of SGA and reduction of stillbirth; to the best of our knowledge, there are no reported randomised control trials. Our aim was to determine if GAP improves antenatal detection of SGA compared to standard care. METHODS AND FINDINGS: This was a pragmatic, superiority, 2-arm, parallel group, open, cluster randomised control trial. Maternity units in England were eligible to participate in the study, except if they had already implemented GAP. All women who gave birth in participating clusters (maternity units) during the year prior to randomisation and during the trial (November 2016 to February 2019) were included. Multiple pregnancies, fetal abnormalities or births before 24+1 weeks were excluded. Clusters were randomised to immediate implementation of GAP, an antenatal care package aimed at improving detection of SGA as a means to reduce the rate of stillbirth, or to standard care. Randomisation by random permutation was stratified by time of study inclusion and cluster size. Data were obtained from hospital electronic records for 12 months prerandomisation, the washout period (interval between randomisation and data collection of outcomes), and the outcome period (last 6 months of the study). The primary outcome was ultrasound detection of SGA (estimated fetal weight <10th centile using customised centiles (intervention) or Hadlock centiles (standard care)) confirmed at birth (birthweight <10th centile by both customised and population centiles). Secondary outcomes were maternal and neonatal outcomes, including induction of labour, gestational age at delivery, mode of birth, neonatal morbidity, and stillbirth/perinatal mortality. A 2-stage cluster-summary statistical approach calculated the absolute difference (inter

Published
2022

7. Factors associated with hospitalization due to COVID-19 in patients with psoriasis: insights from a global registry

Author

Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Calzavara Pinton, P, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Mahil S, Dand N, Mason K, Yiu Z, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Calzavara Pinton P, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh E, Feldman S, McMahon D, Freeman E, Gisondi P, Puig L, Warren R, Di Meglio P, Langan S, Capon F, Griffiths C, Barker J, Smith C., Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Calzavara Pinton, P, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Mahil S, Dand N, Mason K, Yiu Z, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Calzavara Pinton P, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh E, Feldman S, McMahon D, Freeman E, Gisondi P, Puig L, Warren R, Di Meglio P, Langan S, Capon F, Griffiths C, Barker J, and Smith C.

Published
2020

8. Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.

Author

Bechman, K, primary, Cook, ES, additional, Dand, N, additional, Yiu, ZZN, additional, Tsakok, T, additional, Meynell, F, additional, Coker, B, additional, Vincent, A, additional, Bachelez, H, additional, Barbosa, I, additional, Brown, MA, additional, Capon, F, additional, Contreras, CR, additional, De La Cruz, C, additional, Di Meglio, P, additional, Gisondi, P, additional, Jullien, D, additional, Kelly, J, additional, Lambert, J, additional, Lancelot, C, additional, Langan, SM, additional, Mason, KJ, additional, McAteer, H, additional, Moorhead, L, additional, Naldi, L, additional, Norton, S, additional, Puig, L, additional, Spuls, P, additional, Torres, T, additional, Urmston, D, additional, Vesty, A, additional, Warren, RB, additional, Waweru, H, additional, Weinman, J, additional, Griffiths, CEM, additional, Barker, JN, additional, Smith, CH, additional, Galloway, JB, additional, and Mahil, SK, additional

Published
2022
Full Text
View/download PDF

10. Factors associated with hospitalization due to COVID-19 in patients with psoriasis: insights from a global registry

Author

Mahil, S., Dand, N., Mason, K., Yiu, Z., Tsakok, T., Meynell, F., Coker, B., Mcateer, H., Moorhead, L., Mackenzie, T., Calzavara Pinton, P., Rivera, R., Mahe, E., Andrea Carugno, Magnano, M., Rech, G., Balogh, E., Feldman, S., Mcmahon, D., Freeman, E., Gisondi, P., Puig, L., Warren, R., Di Meglio, P., Langan, S., Capon, F., Griffiths, C., Barker, J., Smith, C., Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Calzavara Pinton, P, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, and Smith, C

Subjects
psoriasis, COVID-19
Published
2020

11. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type : a cross-sectional patient survey

Author

Mahil, S. K., Yates, M., Langan, S. M., Yiu, Z. Z.N., Tsakok, T., Dand, N., Mason, K. J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Bruce, I. N., Capon, F., Contreras, C. R., Cope, A. P., De La Cruz, C., Di Meglio, P., Gisondi, P., Hyrich, K., Jullien, D., Lambert, J., Marzo-Ortega, H., McInnes, I., Naldi, L., Norton, S., Puig, L., Sengupta, R., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Griffiths, C. E.M., Barker, J. N., Brown, M. A., Galloway, J. B., Smith, C. H., other, and, Mahil, S. K., Yates, M., Langan, S. M., Yiu, Z. Z.N., Tsakok, T., Dand, N., Mason, K. J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Bruce, I. N., Capon, F., Contreras, C. R., Cope, A. P., De La Cruz, C., Di Meglio, P., Gisondi, P., Hyrich, K., Jullien, D., Lambert, J., Marzo-Ortega, H., McInnes, I., Naldi, L., Norton, S., Puig, L., Sengupta, R., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Griffiths, C. E.M., Barker, J. N., Brown, M. A., Galloway, J. B., Smith, C. H., and other, and

Abstract

Background: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. Objectives: We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. Methods: Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model. Results: Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term ‘shielding’). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35–1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23–1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05–1·24), obesity (OR 1·37, 95% CI 1·23–1·54), comorbidity burden (OR 1·43, 95% CI 1·15–1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27–1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36–1·80). Modest differences in the proportion shielding were observed across nations. Conclusions: Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contr

Published
2021

12. Describing the burden of the COVID-19 pandemic in people with psoriasis : findings from a global cross-sectional study

Author

Mahil, S. K., Yates, Mark, Yiu, Z. Z.N., Langan, S. M., Tsakok, T., Dand, N., Mason, Kayleigh J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Capon, F., Contreras, C. R., De La Cruz, C., Di Meglio, P., Gisondi, P., Jullien, D., Lambert, J., Naldi, L., Norton, S., Puig, L., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Brown, M. A., Galloway, J. B., Griffiths, C. M., Barker, J. N., Smith, C. H., other, and, Mahil, S. K., Yates, Mark, Yiu, Z. Z.N., Langan, S. M., Tsakok, T., Dand, N., Mason, Kayleigh J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Capon, F., Contreras, C. R., De La Cruz, C., Di Meglio, P., Gisondi, P., Jullien, D., Lambert, J., Naldi, L., Norton, S., Puig, L., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Brown, M. A., Galloway, J. B., Griffiths, C. M., Barker, J. N., Smith, C. H., and other, and

Published
2021

13. Using electronic patient records to assess the effect of a complex antenatal intervention in a cluster randomised controlled trial-data management experience from the DESiGN Trial team.

Author

Relph, S, Elstad, M, Coker, B, Vieira, MC, Moitt, N, Gutierrez, WM, Khalil, A, Sandall, J, Copas, A, Lawlor, DA, Pasupathy, D, DESIGN Trial team, Relph, S, Elstad, M, Coker, B, Vieira, MC, Moitt, N, Gutierrez, WM, Khalil, A, Sandall, J, Copas, A, Lawlor, DA, Pasupathy, D, and DESIGN Trial team

Abstract

Background The use of electronic patient records for assessing outcomes in clinical trials is a methodological strategy intended to drive faster and more cost-efficient acquisition of results. The aim of this manuscript was to outline the data collection and management considerations of a maternity and perinatal clinical trial using data from electronic patient records, exemplifying the DESiGN Trial as a case study. Methods The DESiGN Trial is a cluster randomised control trial assessing the effect of a complex intervention versus standard care for identifying small for gestational age foetuses. Data on maternal/perinatal characteristics and outcomes including infants admitted to neonatal care, parameters from foetal ultrasound and details of hospital activity for health-economic evaluation were collected at two time points from four types of electronic patient records held in 22 different electronic record systems at the 13 research clusters. Data were pseudonymised on site using a bespoke Microsoft Excel macro and securely transferred to the central data store. Data quality checks were undertaken. Rules for data harmonisation of the raw data were developed and a data dictionary produced, along with rules and assumptions for data linkage of the datasets. The dictionary included descriptions of the rationale and assumptions for data harmonisation and quality checks. Results Data were collected on 182,052 babies from 178,350 pregnancies in 165,397 unique women. Data availability and completeness varied across research sites; each of eight variables which were key to calculation of the primary outcome were completely missing in median 3 (range 1–4) clusters at the time of the first data download. This improved by the second data download following clarification of instructions to the research sites (each of the eight key variables were completely missing in median 1 (range 0–1) cluster at the second time point). Common data management challenges were harmonising a sin

Published
2021

14. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study

Author

Mahil, SK, primary, Yates, M, additional, Yiu, ZZN, additional, Langan, SM, additional, Tsakok, T, additional, Dand, N, additional, Mason, KJ, additional, McAteer, H, additional, Meynell, F, additional, Coker, B, additional, Vincent, A, additional, Urmston, D, additional, Vesty, A, additional, Kelly, J, additional, Lancelot, C, additional, Moorhead, L, additional, Bachelez, H, additional, Capon, F, additional, Contreras, CR, additional, De La Cruz, C, additional, Meglio, P Di, additional, Gisondi, P, additional, Jullien, D, additional, Lambert, J, additional, Naldi, L, additional, Norton, S, additional, Puig, L, additional, Spuls, P, additional, Torres, T, additional, Warren, RB, additional, Waweru, H, additional, Weinman, J, additional, Brown, MA, additional, Galloway, JB, additional, Griffiths, CM, additional, Barker, JN, additional, and Smith, CH, additional

Published
2021
Full Text
View/download PDF

16. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma

Author

Jin, H., primary, Chalkidou, A., additional, Hawkins, M., additional, Summers, J., additional, Eddy, S., additional, Peacock, J.L., additional, Coker, B., additional, Kartha, M.R., additional, Good, J., additional, Pennington, M., additional, Baker, A., additional, Berry, L., additional, Hatton, M., additional, Henry, A., additional, Lee, J., additional, Patel, R., additional, Powell, H., additional, Sahdra, S., additional, Slevin, N., additional, Van As, N., additional, Webster, G., additional, and Zou, L., additional

Published
2021
Full Text
View/download PDF

17. Steamfitters Local Union No. 420 Welfare Fund v. Philip Morris: is Swift v. Tyson dead?

Author

Cleveland, Coker B.

Subjects
Proximate cause (Law) -- Laws, regulations and rules, Federal jurisdiction -- Laws, regulations and rules, Negligence -- Laws, regulations and rules, Exclusive and concurrent legislative powers -- Laws, regulations and rules, Iron Workers Local Union No. 17 v. Philip Morris, Inc. (23 F. Supp. 2d 771 (N.D. Ohio 1998)), Swift v. Tyson (41 U.S. (16 Pet.) 1 (1842)), Erie Railroad v. Tompkins (304 U.S. 64 (1938))
Published
2001

19. Risk mitigating behaviours in people with inflammatory joint and skin disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey

Author

Mahil, SK, primary, Yates, M, additional, Langan, SM, additional, Yiu, ZZN, additional, Tsakok, T, additional, Dand, N, additional, Mason, KJ, additional, McAteer, H, additional, Meynell, F, additional, Coker, B, additional, Vincent, A, additional, Urmston, D, additional, Vesty, A, additional, Kelly, J, additional, Lancelot, C, additional, Moorhead, L, additional, Bachelez, H, additional, Bruce, IN, additional, Capon, F, additional, Contreras, CR, additional, Cope, AP, additional, De La Cruz, C, additional, Di Meglio, P, additional, Gisondi, P, additional, Hyrich, K, additional, Jullien, D, additional, Lambert, J, additional, Waweru, H, additional, Marzo-Ortega, H, additional, McKinnes, I, additional, Naldi, L, additional, Norton, S, additional, Puig, L, additional, Sengupta, R, additional, Spuls, P, additional, Torres, T, additional, Warren, RB, additional, Weinman, J, additional, Griffiths, CM, additional, Barker, JN, additional, Brown, MA, additional, Galloway, JB, additional, and Smith, CH, additional

Published
2020
Full Text
View/download PDF

21. Arousal increases self-disclosure

Author

Coker, B, McGill, AL, Coker, B, and McGill, AL

Abstract

This research tests the hypothesis that arousal increases self-disclosure. We find that affective arousal increases the amount (study 1) and the severity (study 2) of self-disclosure, and that self-disclosure is also increased by physiological arousal (study 3). We further explore the moderating effect of thought frequency on the arousal-disclosure relationship, finding that often-thought-about thoughts are more likely to be disclosed than less thought-about thoughts. This research has practical importance in terms of understanding when and why people self-disclose personal information, and enriches our understanding of the theoretical relationship between arousal and information sharing.

Published
2020

22. Arousal enhances herding tendencies when decision making

Author

Coker, B and Coker, B

Abstract

This research examines how arousal enhances consumer tendencies to be influenced by the majority when decision making, also known as “herding.” Physiological arousal was manipulated in three controlled experiments, using discrete choice decisions as the dependent variable. The results suggest that arousal enhances tendencies to choose more popular options and that deindividuation mediates the effect of arousal on choice. This research enriches our understanding of the theoretical relationship between arousal and consumer decision making, by suggesting that arousal increases herding. The practical relevance of our findings suggests that strategies to increase herding effects, such as “popular choice” stickers and social media metrics, may be enhanced by making the experience more arousing.

Published
2020

23. Describing the burden of the COVID‐19 pandemic in people with psoriasis: findings from a global cross‐sectional study.

Author

Mahil, S.K., Yates, M., Yiu, Z.Z.N., Langan, S.M., Tsakok, T., Dand, N., Mason, K.J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Capon, F., Contreras, C.R., and De La Cruz, C.

Subjects
COVID-19 pandemic, PSORIATIC arthritis, CROSS-sectional method, MENTAL illness, PSORIASIS, STAY-at-home orders
Abstract

Prof. Warren reports grants and personal fees from Abbvie, grants and personal fees from Celgene, grants and personal fees from Eli Lilly, grants and personal fees from Novartis, personal fees from Sanofi, grants and personal fees from UCB|, grants and personal fees from Almirall, grants and personal fees from Amgen, grants and personal fees from Janssen, grants and personal fees from Leo, grants and personal fees from Pfizer, personal fees from Arena, personal fees from Avillion, personal fees from Bristol Myers Squibb, personal fees from Boehringer Ingelheim, outside the submitted work. We are grateful to all the patients who have contributed to PsoProtect I Me i , the professional and patient organisations who supported or promoted PsoProtect I M i e and for the input of Prof Lars Iversen, Prof Nick Reynolds, Prof Joel Gelfand, Ms Christine Janus and Ms Melissa Sweeney through their vital contributions. Dr. Di Meglio reports grants and personal fees from UCB, personal fees from Novartis, personal fees from Janssen, outside the submitted work. [Extracted from the article]

Published
2021
Full Text
View/download PDF

25. Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*.

Author

Mahil, S.K., Yates, M., Langan, S.M., Yiu, Z.Z.N., Tsakok, T., Dand, N., Mason, K.J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Bruce, I.N., Capon, F., and Contreras, C.R.

Subjects
COVID-19 pandemic, COVID-19, SKIN diseases, JOINT diseases, MUSCULOSKELETAL system diseases
Abstract

Summary: Background: Registry data suggest that people with immune‐mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID‐19) outcomes compared with patients receiving no systemic treatments. Objectives: We used international patient survey data to explore the hypothesis that greater risk‐mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. Methods: Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk‐mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed‐effects model. Results: Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk‐mitigating behaviour (classified here under the umbrella term 'shielding'). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35–1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23–1·56). Shielding was associated with established risk factors for severe COVID‐19 [male sex (OR 1·14, 95% CI 1·05–1·24), obesity (OR 1·37, 95% CI 1·23–1·54), comorbidity burden (OR 1·43, 95% CI 1·15–1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27–1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36–1·80). Modest differences in the proportion shielding were observed across nations. Conclusions: Greater risk‐mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID‐19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence‐based patient communication on risk‐mitigation strategies and may help inform updated public health guidelines as the pandemic continues. What is already known about this topic? At the beginning of the coronavirus disease 2019 (COVID‐19) pandemic, patients with immune‐mediated inflammatory diseases (IMIDs) on targeted systemic therapies were considered to be at higher risk of severe COVID‐19.Subsequent clinician‐reported registry data suggest that targeted systemic therapy use is associated with fewer adverse COVID‐19 outcomes compared with no systemic therapy. What does this study add? We characterize shielding behaviour in 3720 patients with IMIDs from a global self‐report survey.Use of targeted systemic therapy associates with increased shielding behaviour, compared with standard systemics or no therapy, as do demographic risk factors for severe COVID‐19 including male sex and obesity.Greater risk‐mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID‐19 outcomes.Behaviour variation across treatment groups reinforces the need for clear, evidence‐based patient communication on risk‐mitigation strategies.These data may help to inform updated public health guidelines as the pandemic continues. Linked Comment: G. Becher and A.D. Burden. Br J Dermatol 2021; 185:7–8. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

28. Variations in Health-Related Quality of Life (HRQoL) and survival 1 year after stroke: five European population-based registers

Author

Ayis, S., primary, Wellwood, I., additional, Rudd, A. G., additional, McKevitt, C., additional, Parkin, D., additional, Wolfe, C. D. A., additional, Giroud, M., additional, Inzitari, D., additional, Torrent, M., additional, Sienkiewicz-Jarosz, H., additional, Czlonkowska, A., additional, Sarti, C., additional, Lamassa, M., additional, Nencini, P., additional, Poggesi, A., additional, Pescini, F., additional, Cramaro, A., additional, Magnani, E., additional, Romani, I., additional, Baldereschi, M., additional, Sopagiene, D., additional, Kranciukaite, D., additional, Rodriguez-Mera, J., additional, G uszkiewicz, M., additional, Pniewski, J., additional, Coker, B., additional, and Moltchanov, V., additional

Published
2015
Full Text
View/download PDF

29. Variations in acute stroke care and the impact of organised care on survival from a European perspective: the European Registers of Stroke (EROS) investigators

Author

Ayis, S. A., primary, Coker, B., additional, Bhalla, A., additional, Wellwood, I., additional, Rudd, A. G., additional, Di Carlo, A., additional, Bejot, Y., additional, Ryglewicz, D., additional, Rastenyte, D., additional, Langhorne, P., additional, Dennis, M. S., additional, McKevitt, C., additional, and Wolfe, C. D. A., additional

Published
2013
Full Text
View/download PDF

34. The Earth Resources Laboratory Applications Software (ELAS) in university research and education: An operator oriented geobased information system

Author

Coker, B. L, Kind, T. C, Smith, W. F., Jr, and Weber, N. V

Subjects
Earth Resources And Remote Sensing
Abstract

Created for analyzing and processing digital data such as that collected by multispectral scanners or digitized from maps, ELAS is designed for ease of user operation and includes its own FORTRAN operating monitor and an expandable set of application modules which are FORTRAN overlays. On those machines that do not support FORTRAN overlaying, the modules exist as subprograms. The subsystem can be implemented on most 16-bit or 32-bit machines and is capable of, but not limited to, operating on low-cost minicomputer systems. The recommended hardware configuration for ELAS and a representative listing of some operating and application modules are presented.

Published
1981

35. Growing on

Author

Coker, Britt

Published
2022

38. Viewpoints

Author

Williamson, Pauline R., Atkins, Joseph, Elphick, John, Booth, Ron, Nelson, Oscar, Curtis, Patricia, Miller, Jim, Hamilton, Charles F., Coker, B., Bownds, Derek, and Rohsner, Art

Subjects
General interest, News, opinion and commentary
Published
1996

40. Moving to multi-channel e-commerce: lessons learned from a case study of an apparel and home-ware catalogue company.

Author

Tate M, Coker B, and Hope B

Abstract

After the 'dot-com bust' there is considerable evidence that multi-channel retailers are more successful than purely on-line retailers. We talked to the management team of one of the most successful multi-channel apparel and home-ware retailers in Australasia about the business and technology factors that enabled their growth. We found seven key business strategies enabled growth and expansion into new channels, including e-commerce: integrated operational functions, channel synergy, logistics management, presenting a consistent brand, effective customer management, learning from customers, and informed imitation. These strategies were supported by integrated information technology applications. At the time of our study, the recently added Internet channel was not fully integrated with the other core systems. This was being adequately managed through strong internal processes but had the potential to constrain future growth in this channel. We examine the factors that led to the firm's success and some of the issues and constraints they are experiencing. We then extract from their experiences the lessons that can be learned by other organisations. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

44. Aquamango

Author

Coker, Britt

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results